| Identification | Back Directory | [Name]
LEI-105
(LEI105) | [CAS]
1800327-36-9 | [Synonyms]
LEI105
LEI-105
(LEI105)
6-Phenyl-1-(6-(p-tolyl)oxazolo[4,5-b]pyridin-2-yl)hexan-1- one | [Molecular Formula]
C25H24N2O2 | [MOL File]
1800327-36-9.mol | [Molecular Weight]
384.47 |
| Hazard Information | Back Directory | [Description]
LEI105 is a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor. Diacylglycerol lipase (DAGL)-α and -β are enzymes responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG). | [Uses]
LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation[1]. | [References]
[1] Baggelaar MP, et al. Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons. J Am Chem Soc. 2015 Jul 15;137(27):8851-7. DOI:10.1021/jacs.5b04883 |
|
|